Sequential maximum androgen blockade (MAB) in minimally symptomatic prostate cancer progressing after initial MAB: Two case reports - Abstract

The management of castrate-resistant prostate cancer progressing after maximum androgen blockade (MAB) has evolved in the last decade with the development of several novel therapeutic options.

However, the initial therapeutic strategy in these patients usually involves withdrawal of anti-androgen that can be associated with biochemical response in approximately 20% of patients. Notably, we have observed evidence of sustained biochemical response in two patients following second- and third-line MAB using rechallenge schedule of previously administered anti-androgen after latent interval. The possibility of response following sequential MAB using the same anti-androgen agent has not yet been reported.

Written by:
Hingorani M, Dixit S, Bashir F, Butt M, Hawkyard S, Khafagy R, Robertson A.   Are you the author?
Department of Clinical Oncology, Castle Hill Hospital, Cottingham, HU16 5JQ, UK; Department of Urology, Scarborough General Hospital, Scarborough, YO12 6QL, UK.

Reference: Cancer Biol Med. 2014 Dec;11(4):277-80.
doi: 10.7497/j.issn.2095-3941.2014.04.007


PubMed Abstract
PMID: 25610714

UroToday.com Prostate Cancer Section

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe